AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Sulfachloropyridazine works by inhibiting the growth and reproduction of susceptible bacteria. It interferes with the synthesis of dihydrofolic acid in bacteria, which is essential for the production of nucleic acids and proteins required for bacterial growth. By disrupting folate metabolism, sulfachloropyridazine effectively kills or inhibits the growth of bacterial pathogens.
Broad-Spectrum Antibiotic: Sulfachloropyridazine exhibits broad-spectrum antibacterial activity against a variety of gram-positive and gram-negative bacteria, including Escherichia coli, Salmonella spp., Pasteurella spp., and various respiratory and urinary tract pathogens in animals.
Veterinary Use: Sulfachloropyridazine is commonly used in veterinary medicine for the treatment and prevention of bacterial infections in livestock, poultry, and other animals. It may be administered orally or parenterally (via injection) depending on the type and severity of the infection.
Control of Bacterial Diseases: Sulfachloropyridazine is used to control and manage bacterial diseases in animals, including respiratory infections, enteric diseases, urinary tract infections, and systemic bacterial infections. It is often included in feed or water medication formulations for mass treatment of livestock populations.
Dosage and Administration: The dosage and administration of sulfachloropyridazine vary depending on the species of animal being treated, the severity of the infection, and the formulation of the medication. It is important to follow the prescribing veterinarian's instructions carefully and administer the medication for the full duration of treatment to ensure effective bacterial eradication and prevent the development of antimicrobial resistance.
Safety and Adverse Effects: While sulfachloropyridazine is generally considered safe when used appropriately in animals, adverse effects may occur, including allergic reactions, gastrointestinal disturbances (e.g., diarrhea, vomiting), and hypersensitivity reactions. In rare cases, sulfonamide antibiotics may cause more severe adverse effects such as hematological abnormalities (e.g., hemolytic anemia, thrombocytopenia) or skin reactions (e.g., dermatitis, photosensitivity).
Drug Interactions: Sulfachloropyridazine may interact with other medications or substances, including other antibiotics, anticoagulants, diuretics, and anticonvulsants, among others. It is important to inform the prescribing veterinarian about any concurrent medications or medical conditions to avoid potential drug interactions or adverse effects.
Regulatory Considerations: The use of sulfachloropyridazine in animals is subject to regulatory oversight and may require veterinary prescription or supervision in some jurisdictions. It is important to comply with local regulations and guidelines regarding the use of antimicrobial agents in animal healthcare to promote responsible antibiotic use and minimize the risk of antimicrobial resistance.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
species | Streptococcus thermophilus | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Parabacteroides | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
1 | 0 | Bacteroides uniformis | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
1 | 0 | Bacteroides fragilis | species | Decreases |
1 | 0 | Parabacteroides merdae | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
0 | 1 | Bacteroides humanifaecis | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Bacteroides sp. A1C1 | species | Decreases |
0 | 1 | Streptococcus vestibularis | species | Decreases |
0 | 1 | Bacteroides sp. CACC 737 | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
0 | 1 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Bacteroides sp. HF-162 | species | Decreases |
0 | 1 | Streptococcus gordonii | species | Decreases |
0 | 1 | Streptococcus sp. oral taxon 061 | species | Decreases |
0 | 1 | Streptococcus australis | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Streptococcus lactarius | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
1 | 0 | Parabacteroides distasonis | species | Decreases |
0 | 1 | Streptococcus oralis | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
0 | 1 | Streptococcus sp. Marseille-Q6470 | species | Decreases |
0 | 1 | Streptococcus sp. oral taxon 431 | species | Decreases |
0 | 1 | Bacteroides luhongzhouii | species | Decreases |
0 | 1 | Streptococcus infantis | species | Decreases |
0 | 1 | Bacteroides faecium | species | Decreases |
0 | 1 | Streptococcus sanguinis | species | Decreases |
0 | 1 | Streptococcus ilei | species | Decreases |
0 | 1 | Streptococcus thermophilus | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Mediterraneibacter gnavus | species | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
ADHD | 1.3 | 0.1 | 12 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | -0.1 | |
Allergic Rhinitis (Hay Fever) | 1.1 | 1.1 | 0 |
Allergies | 1.9 | 0.5 | 2.8 |
Allergy to milk products | 0.8 | 0.7 | 0.14 |
Alopecia (Hair Loss) | 0.1 | 0.1 | |
Alzheimer's disease | 2.5 | 1.6 | 0.56 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.5 | 0.8 |
Ankylosing spondylitis | 1.8 | 0.5 | 2.6 |
Anorexia Nervosa | 0.5 | 1.2 | -1.4 |
Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
Asthma | 2.7 | 0.7 | 2.86 |
Atherosclerosis | 1.5 | 1.5 | |
Atrial fibrillation | 1.3 | 0.9 | 0.44 |
Autism | 2.2 | 2.6 | -0.18 |
Autoimmune Disease | 0.8 | 0.8 | |
Barrett esophagus cancer | 0.2 | 0.4 | -1 |
benign prostatic hyperplasia | 0.4 | 0.3 | 0.33 |
Biofilm | 1.6 | 1.6 | |
Bipolar Disorder | 1 | 0.1 | 9 |
Brain Trauma | 0.4 | 0.3 | 0.33 |
Breast Cancer | 0.9 | 0.9 | |
Cancer (General) | 0.2 | 0.2 | 0 |
Carcinoma | 1.7 | 0.4 | 3.25 |
Celiac Disease | 1.7 | 0.4 | 3.25 |
Cerebral Palsy | 0.7 | 0.3 | 1.33 |
Chronic Fatigue Syndrome | 2.3 | 1.2 | 0.92 |
Chronic Kidney Disease | 1 | 1 | |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 0.5 | 3.2 |
Chronic Urticaria (Hives) | 1.2 | 0.5 | 1.4 |
Coagulation / Micro clot triggering bacteria | 1.5 | 0.4 | 2.75 |
Cognitive Function | 0.8 | 0.4 | 1 |
Colorectal Cancer | 3.9 | 0.8 | 3.88 |
Constipation | 0.7 | 0.7 | |
Coronary artery disease | 1.4 | 0.8 | 0.75 |
COVID-19 | 4.2 | 2.6 | 0.62 |
Crohn's Disease | 3.9 | 1.1 | 2.55 |
Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
cystic fibrosis | 0.8 | 0.3 | 1.67 |
d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
deep vein thrombosis | 1.8 | 0.7 | 1.57 |
Denture Wearers Oral Shifts | 1.3 | 1.3 | |
Depression | 3.8 | 1.7 | 1.24 |
Dermatomyositis | 0.4 | 0.4 | |
Eczema | 1 | 1.5 | -0.5 |
Endometriosis | 1.8 | 0.5 | 2.6 |
Eosinophilic Esophagitis | 0.2 | 0.4 | -1 |
Epilepsy | 2.3 | 0.8 | 1.87 |
erectile dysfunction | 0.9 | 0.9 | |
Fibromyalgia | 0.6 | 0.9 | -0.5 |
Functional constipation / chronic idiopathic constipation | 2.3 | 0.9 | 1.56 |
gallstone disease (gsd) | 1.4 | 0.2 | 6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.4 | 1.5 |
Generalized anxiety disorder | 1.9 | 0.7 | 1.71 |
Glioblastoma | 0.4 | -0.4 | |
Gout | 0.7 | 0.2 | 2.5 |
Graves' disease | 0.4 | 0.7 | -0.75 |
Gulf War Syndrome | 0.4 | 1.1 | -1.75 |
Halitosis | 1.2 | 0.4 | 2 |
Hashimoto's thyroiditis | 1 | 0.3 | 2.33 |
Heart Failure | 2.2 | 2.2 | |
hemorrhagic stroke | 0.3 | 0.3 | |
Hidradenitis Suppurativa | 0.8 | 0.8 | |
High Histamine/low DAO | 0.5 | 0.5 | |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
hyperglycemia | 1.7 | 0.4 | 3.25 |
hypertension (High Blood Pressure | 1.6 | 1.8 | -0.13 |
Hypothyroidism | 0.1 | -0.1 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.1 | 1.2 | -0.09 |
Inflammatory Bowel Disease | 4.1 | 2.1 | 0.95 |
Insomnia | 1.3 | 0.7 | 0.86 |
Intelligence | 1.5 | 1.5 | |
Intracranial aneurysms | 0.6 | 0.6 | |
Irritable Bowel Syndrome | 3.1 | 1.4 | 1.21 |
ischemic stroke | 1.3 | 0.7 | 0.86 |
Liver Cirrhosis | 3 | 1.4 | 1.14 |
Long COVID | 2 | 1.2 | 0.67 |
Lung Cancer | 0.5 | 0.5 | |
Lymphoma | 0.4 | 0.4 | |
Mast Cell Issues / mastitis | 1.2 | 1.2 | |
ME/CFS with IBS | 0.4 | 0.3 | 0.33 |
ME/CFS without IBS | 0.7 | 0.4 | 0.75 |
membranous nephropathy | 0.4 | 0.4 | |
Menopause | 0.4 | 0.4 | |
Metabolic Syndrome | 2.6 | 2.1 | 0.24 |
Mood Disorders | 3.4 | 1.8 | 0.89 |
multiple chemical sensitivity [MCS] | 1.1 | 1.1 | |
Multiple Sclerosis | 2.3 | 1.4 | 0.64 |
Multiple system atrophy (MSA) | 0.2 | 0.2 | |
myasthenia gravis | 0.8 | 0.8 | |
neuropathic pain | 0.1 | 0.4 | -3 |
Neuropathy (all types) | 0.5 | 0.4 | 0.25 |
neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 0.3 | 5 |
NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
Obesity | 2 | 2.5 | -0.25 |
obsessive-compulsive disorder | 2.7 | 0.7 | 2.86 |
Osteoarthritis | 1.5 | 0.7 | 1.14 |
Osteoporosis | 0.8 | 0.7 | 0.14 |
pancreatic cancer | 0.7 | 0.4 | 0.75 |
Parkinson's Disease | 3.1 | 1.7 | 0.82 |
Polycystic ovary syndrome | 2.4 | 0.7 | 2.43 |
Premenstrual dysphoric disorder | 0.1 | -0.1 | |
primary biliary cholangitis | 0.4 | 1.1 | -1.75 |
Primary sclerosing cholangitis | 1.2 | 0.3 | 3 |
Psoriasis | 1.4 | 0.5 | 1.8 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 1 | 0.7 |
Schizophrenia | 1.9 | 0.4 | 3.75 |
scoliosis | 0.5 | 0.5 | |
Sjögren syndrome | 0.9 | 1 | -0.11 |
Sleep Apnea | 0.3 | 0.4 | -0.33 |
Slow gastric motility / Gastroparesis | 0.8 | 0.8 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
Stress / posttraumatic stress disorder | 1.3 | 0.6 | 1.17 |
Systemic Lupus Erythematosus | 2 | 2 | |
Tic Disorder | 0.4 | 0.4 | |
Tourette syndrome | 0.4 | 0.3 | 0.33 |
Type 1 Diabetes | 1.6 | 0.7 | 1.29 |
Type 2 Diabetes | 2.6 | 3.2 | -0.23 |
Ulcerative colitis | 2.6 | 2.1 | 0.24 |
Unhealthy Ageing | 1.8 | 0.1 | 17 |
Vitiligo | 1.3 | 0.1 | 12 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]